BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, Keljo D, Waxman J, Otley A, LeLeiko NS, Mack D, Hyams J, Levine A. Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis. 2012;18:55-62. [PMID: 21351206 DOI: 10.1002/ibd.21649] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Minar P, Lehn C, Tsai YT, Jackson K, Rosen MJ, Denson LA. Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab. Crohns Colitis 360 2019;1:otz026. [PMID: 31667468 DOI: 10.1093/crocol/otz026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Levine A, Turner D, Pfeffer Gik T, Amil Dias J, Veres G, Shaoul R, Staiano A, Escher J, Kolho KL, Paerregaard A, Martin de Carpi J, Veereman Wauters G, Koletzko S, Shevah O, Finnby L, Sladek M. Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study. Inflamm Bowel Dis 2014;20:278-85. [PMID: 24390062 DOI: 10.1097/01.MIB.0000437735.11953.68] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 8.8] [Reference Citation Analysis]
3 Carlsen K, Jakobsen C, Kallemose T, Paerregaard A, Riis LB, Munkholm P, Wewer V. F-calprotectin and Blood Markers Correlate to Quality of Life in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2017;65:539-45. [DOI: 10.1097/mpg.0000000000001540] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
4 Dunn KA, Moore-connors J, Macintyre B, Stadnyk A, Thomas NA, Noble A, Mahdi G, Rashid M, Otley AR, Bielawski JP, Van Limbergen J. The Gut Microbiome of Pediatric Crohnʼs Disease Patients Differs from Healthy Controls in Genes That Can Influence the Balance Between a Healthy and Dysregulated Immune Response: . Inflammatory Bowel Diseases 2016;22:2607-18. [DOI: 10.1097/mib.0000000000000949] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 4.6] [Reference Citation Analysis]
5 Turner D, Carle A, Steiner SJ, Margolis PA, Colletti RB, Russell RK, Levine A, Kolho KL, Ruemmele FM; ImproveCareNow Network. Quality Items Required for Running a Paediatric Inflammatory Bowel Disease Centre: An ECCO Paper. J Crohns Colitis 2017;11:981-7. [PMID: 28789473 DOI: 10.1093/ecco-jcc/jjx036] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Diederen K, Gerritsma JJ, Koot BGP, Tabbers MM, Benninga MA, Kindermann A. Do Children and Adolescents With Inflammatory Bowel Disease Complete Clinical Disease Indices Similar to Physicians? J Pediatr Gastroenterol Nutr 2018;66:410-6. [PMID: 28832362 DOI: 10.1097/MPG.0000000000001712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
7 van Tilburg MAL, Claar RL, Romano JM, Langer SL, Drossman DA, Whitehead WE, Abdullah B, Levy RL. Psychological Factors May Play an Important Role in Pediatric Crohn's Disease Symptoms and Disability. J Pediatr 2017;184:94-100.e1. [PMID: 28238483 DOI: 10.1016/j.jpeds.2017.01.058] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
8 Rao A, Standing JF, Naik S, Savage MO, Sanderson IR. Mathematical modelling to restore circulating IGF-1 concentrations in children with Crohn's disease-induced growth failure: a pharmacokinetic study. BMJ Open 2013;3:e002737. [PMID: 23793696 DOI: 10.1136/bmjopen-2013-002737] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
9 Lev-Tzion R, Renbaum P, Beeri R, Ledder O, Mevorach R, Karban A, Koifman E, Efrati E, Muise AM, Chowers Y, Turner D. Rac1 Polymorphisms and Thiopurine Efficacy in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2015;61:404-7. [PMID: 25885881 DOI: 10.1097/MPG.0000000000000820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
10 Stapersma L, van den Brink G, van der Ende J, Bodelier AG, van Wering HM, Hurkmans PCWM, Mearin ML, van der Meulen-de Jong AE, Escher JC, Utens EMWJ. Illness Perceptions and Depression Are Associated with Health-Related Quality of Life in Youth with Inflammatory Bowel Disease. Int J Behav Med 2019;26:415-26. [PMID: 31183787 DOI: 10.1007/s12529-019-09791-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
11 Weiss B, Turner D, Griffiths A, Walters T, Herman-Sucharska I, Coppenrath E, Anupindi SA, Towbin AJ, O'Brien K, Silverstein J, Navas V, Koletzko S, Sladek M, Gavish M, Amitai MM; ImageKids study group. NCT01881490. Simple Endoscopic Score of Crohn Disease and Magnetic Resonance Enterography in Children: Report From ImageKids Study. J Pediatr Gastroenterol Nutr 2019;69:461-5. [PMID: 31136561 DOI: 10.1097/MPG.0000000000002404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Bishop C, Simon H, Suskind D, Lee D, Wahbeh G. Ustekinumab in Pediatric Crohn Disease Patients. Journal of Pediatric Gastroenterology & Nutrition 2016;63:348-51. [DOI: 10.1097/mpg.0000000000001146] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 6.2] [Reference Citation Analysis]
13 Takeuchi I, Kaburaki Y, Arai K, Shimizu H, Hirano Y, Nagata S, Shimizu T. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan. J Gastroenterol Hepatol 2020;35:593-600. [PMID: 31425641 DOI: 10.1111/jgh.14836] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
14 Connors J, Dunn KA, Allott J, Bandsma R, Rashid M, Otley AR, Bielawski JP, Van Limbergen J. The relationship between fecal bile acids and microbiome community structure in pediatric Crohn's disease. ISME J 2020;14:702-13. [PMID: 31796936 DOI: 10.1038/s41396-019-0560-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
15 LeLeiko NS, Lobato D, Hagin S, McQuaid E, Seifer R, Kopel SJ, Boergers J, Nassau J, Suorsa K, Shapiro J. Rates and predictors of oral medication adherence in pediatric patients with IBD. Inflamm Bowel Dis. 2013;19:832-839. [PMID: 23446336 DOI: 10.1097/mib.0b013e3182802b57] [Cited by in Crossref: 34] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
16 Schulman JM, Pritzker L, Shaoul R. Maintenance of Remission with Partial Enteral Nutrition Therapy in Pediatric Crohn's Disease: A Retrospective Study. Can J Gastroenterol Hepatol 2017;2017:5873158. [PMID: 28567370 DOI: 10.1155/2017/5873158] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
17 Carlsen K, Jakobsen C, Houen G, Kallemose T, Paerregaard A, Riis LB, Munkholm P, Wewer V. Self-managed eHealth Disease Monitoring in Children and Adolescents with Inflammatory Bowel Disease: A Randomized Controlled Trial. Inflamm Bowel Dis. 2017;23:357-365. [PMID: 28221247 DOI: 10.1097/mib.0000000000001026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
18 Carlsen K, Malham M, Hansen LF, Petersen JJH, Paerregaard A, Houen G, Wewer V. Serum Calprotectin in Adolescents With Inflammatory Bowel Disease-A Pilot Investigation. J Pediatr Gastroenterol Nutr 2019;68:669-75. [PMID: 30628981 DOI: 10.1097/MPG.0000000000002244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
19 Clarkston K, Tsai YT, Jackson K, Rosen MJ, Denson LA, Minar P. Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients. J Pediatr Gastroenterol Nutr 2019;69:68-74. [PMID: 31232885 DOI: 10.1097/MPG.0000000000002304] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 19.0] [Reference Citation Analysis]
20 Aydemir Y, Pınar A, Hızal G, Demir H, Saltık Temizel İN, Özen H, Akbıyık F, Yüce A. Neutrophil volume distribution width as a new marker in detecting inflammatory bowel disease activation. Int Jnl Lab Hem 2017;39:51-7. [DOI: 10.1111/ijlh.12574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
21 Dhaliwal J, Martincevic I, Williams B, Frost K, Uusoue K, Arpino V, Church P, Walters TD, Griffiths AM, Mouzaki M. Body Composition Using Air Displacement Plethysmography in Children With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2020;71:52-8. [DOI: 10.1097/mpg.0000000000002683] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
22 Dunn KA, Moore-Connors J, MacIntyre B, Stadnyk AW, Thomas NA, Noble A, Mahdi G, Rashid M, Otley AR, Bielawski JP, Van Limbergen J. Early Changes in Microbial Community Structure Are Associated with Sustained Remission After Nutritional Treatment of Pediatric Crohn's Disease. Inflamm Bowel Dis. 2016;22:2853-2862. [PMID: 27805918 DOI: 10.1097/mib.0000000000000956] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 13.7] [Reference Citation Analysis]
23 Pai N, Popov J, Hill L, Hartung E. Protocol for a double-blind, randomised, placebo-controlled pilot study for assessing the feasibility and efficacy of faecal microbiota transplant in a paediatric Crohn's disease population: PediCRaFT Trial. BMJ Open 2019;9:e030120. [PMID: 31784432 DOI: 10.1136/bmjopen-2019-030120] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Sun H, Papadopoulos EJ, Hyams JS, Griebel D, Lee JJ, Tomaino J, Mulberg AE. Well-Defined and Reliable Clinical Outcome Assessments for Pediatric Crohn Disease: A Critical Need for Drug Development. Journal of Pediatric Gastroenterology & Nutrition 2015;60:729-36. [DOI: 10.1097/mpg.0000000000000793] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
25 Ito N, Takeuchi I, Kyodo R, Hirano Y, Sato T, Usami M, Shimizu H, Shimizu T, Arai K. Features and Outcomes of Children with Ulcerative Colitis who Undergo a Diagnostic Change: A Single-Center Experience. Pediatr Gastroenterol Hepatol Nutr 2021;24:357-65. [PMID: 34316470 DOI: 10.5223/pghn.2021.24.4.357] [Reference Citation Analysis]
26 Bashir NS, Walters TD, Griffiths AM, Ungar WJ. An Assessment of the Validity and Reliability of the Pediatric Child Health Utility 9D in Children with Inflammatory Bowel Disease. Children (Basel) 2021;8:343. [PMID: 33925356 DOI: 10.3390/children8050343] [Reference Citation Analysis]
27 Leleiko NS, Lobato D, Hagin S, Hayes C, Mcquaid EL, Seifer R, Kopel SJ, Boergers J, Nassau J, Suorsa K, Shapiro J, Bancroft B. 6-Thioguanine Levels in Pediatric IBD Patients: Adherence Is More Important than Dose. Inflammatory Bowel Diseases 2013;19:2652-8. [DOI: 10.1097/01.mib.0000436960.00405.56] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Cozijnsen M, Duif V, Kokke F, Kindermann A, van Rheenen P, de Meij T, Schaart M, Damen G, Norbruis O, Pelleboer R, Van den Neucker A, van Wering H, Hummel T, Oudshoorn J, Escher J, de Ridder L. Adalimumab Therapy in Children With Crohn Disease Previously Treated With Infliximab. Journal of Pediatric Gastroenterology & Nutrition 2015;60:205-10. [DOI: 10.1097/mpg.0000000000000589] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
29 Church PC, Greer MC, Cytter-Kuint R, Doria AS, Griffiths AM, Turner D, Walters TD, Feldman BM. Magnetic resonance enterography has good inter-rater agreement and diagnostic accuracy for detecting inflammation in pediatric Crohn disease. Pediatr Radiol 2017;47:565-75. [PMID: 28283726 DOI: 10.1007/s00247-017-3790-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
30 Xiong Y, Mizuno T, Colman R, Hyams J, Noe JD, Boyle B, Tsai YT, Dong M, Jackson K, Punt N, Rosen MJ, Denson LA, Vinks AA, Minar P. Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Clin Pharmacol Ther 2021;109:1639-47. [PMID: 33354765 DOI: 10.1002/cpt.2148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Ricciuto A, Fish JR, Tomalty DE, Carman N, Crowley E, Popalis C, Muise A, Walters TD, Griffiths AM, Church PC. Diagnostic delay in Canadian children with inflammatory bowel disease is more common in Crohn's disease and associated with decreased height. Arch Dis Child. 2018;103:319-326. [PMID: 28794097 DOI: 10.1136/archdischild-2017-313060] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
32 Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori M, Cohen S, Peleg S, Shamaly H, On A, Millman P, Abramas L, Ziv-Baran T, Grant S, Abitbol G, Dunn KA, Bielawski JP, Van Limbergen J. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology. 2019;157:440-450. [PMID: 31170412 DOI: 10.1053/j.gastro.2019.04.021] [Cited by in Crossref: 135] [Cited by in F6Publishing: 110] [Article Influence: 67.5] [Reference Citation Analysis]
33 Chavannes M, Martinez-vinson C, Hart L, Kaniki N, Chao C, Lawrence S, Jacobson K, Hugot J, Viala J, Deslandres C, Jantchou P, Seidman EG. Management of Paediatric Patients With Medically Refractory Crohn’s Disease Using Ustekinumab: A Multi-Centred Cohort Study. Journal of Crohn's and Colitis 2019;13:578-84. [DOI: 10.1093/ecco-jcc/jjy206] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
34 Ruemmele FM, Hyams JS, Otley A, Griffiths A, Kolho KL, Dias JA, Levine A, Escher JC, Taminiau J, Veres G, Colombel JF, Vermeire S, Wilson DC, Turner D. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut. 2015;64:438-446. [PMID: 24821616 DOI: 10.1136/gutjnl-2014-307008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 6.6] [Reference Citation Analysis]
35 Carlsen K, Houen G, Jakobsen C, Kallemose T, Paerregaard A, Riis LB, Munkholm P, Wewer V. Individualized Infliximab Treatment Guided by Patient-managed eHealth in Children and Adolescents with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1473-82. [PMID: 28617758 DOI: 10.1097/MIB.0000000000001170] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 8.3] [Reference Citation Analysis]
36 Jongsma MME, Aardoom MA, Cozijnsen MA, van Pieterson M, de Meij T, Groeneweg M, Norbruis OF, Wolters VM, van Wering HM, Hojsak I, Kolho KL, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg-Roord STA, Schreurs MWJ, Rizopoulos D, Doukas M, Escher JC, Samsom JN, de Ridder L. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial. Gut 2020:gutjnl-2020-322339. [PMID: 33384335 DOI: 10.1136/gutjnl-2020-322339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
37 Carlsen K, Hald M, Dubinsky MC, Keefer L, Wewer V. A Personalized eHealth Transition Concept for Adolescents With Inflammatory Bowel Disease: Design of Intervention. JMIR Pediatr Parent 2019;2:e12258. [PMID: 31518331 DOI: 10.2196/12258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Dolinger MT, Spencer EA, Lai J, Dunkin D, Dubinsky MC. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1210-4. [PMID: 33125058 DOI: 10.1093/ibd/izaa277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Kim FS, Patel PV, Stekol E, Ali S, Hamandi H, Heyman MB, Verstraete SG. Experience Using Ustekinumab in Pediatric Patients With Medically Refractory Crohn Disease. J Pediatr Gastroenterol Nutr 2021;73:610-4. [PMID: 34415711 DOI: 10.1097/MPG.0000000000003230] [Reference Citation Analysis]
40 Zaidi D, Bording-Jorgensen M, Huynh HQ, Carroll MW, Turcotte JF, Sergi C, Liu J, Wine E. Increased Epithelial Gap Density in the Noninflamed Duodenum of Children With Inflammatory Bowel Diseases. J Pediatr Gastroenterol Nutr 2016;63:644-50. [PMID: 26933801 DOI: 10.1097/MPG.0000000000001182] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
41 Logan M, Clark CM, Ijaz UZ, Gervais L, Duncan H, Garrick V, Curtis L, Buchanan E, Cardigan T, Armstrong L, Delahunty C, Flynn DM, Barclay AR, Tayler R, McDonald E, Milling S, Hansen RK, Gerasimidis K, Russell RK. The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction. Aliment Pharmacol Ther 2019;50:664-74. [PMID: 31342536 DOI: 10.1111/apt.15425] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
42 Sun H, Vesely R, Lee KJ, Klein A, Ikima M, Mulberg AE. Pediatric Crohn Disease Clinical Outcome Assessments and Biomarkers: Current State and Path Forward for Global Collaboration. Journal of Pediatric Gastroenterology & Nutrition 2017;64:368-72. [DOI: 10.1097/mpg.0000000000001284] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
43 Diederen K, Krom H, Koole JCD, Benninga MA, Kindermann A. Diet and Anthropometrics of Children With Inflammatory Bowel Disease: A Comparison With the General Population. Inflamm Bowel Dis 2018;24:1632-40. [PMID: 29697827 DOI: 10.1093/ibd/izy027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
44 Ormsby MJ, Logan M, Johnson SA, McIntosh A, Fallata G, Papadopoulou R, Papachristou E, Hold GL, Hansen R, Ijaz UZ, Russell RK, Gerasimidis K, Wall DM. Inflammation associated ethanolamine facilitates infection by Crohn's disease-linked adherent-invasive Escherichia coli. EBioMedicine 2019;43:325-32. [PMID: 31036531 DOI: 10.1016/j.ebiom.2019.03.071] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
45 Piester T, Frymoyer A, Christofferson M, Yu H, Bass D, Park KT. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:227-34. [PMID: 29361094 DOI: 10.1093/ibd/izx037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
46 Altowati MM, Shepherd S, Mcmillan M, Mcgrogan P, Russell R, Ahmed SF, Wong SC. Persistence of Muscle-bone Deficits Following Anti-tumour Necrosis Factor Therapy in Adolescents With Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2018;67:738-44. [DOI: 10.1097/mpg.0000000000002099] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Brückner A, Werkstetter KJ, Frivolt K, Shokry E, Ahmed M, Metwaly A, Marques JG, Uhl O, Krohn K, Hajji M, Otte S, Pozza SB, Bufler P, Liptay S, Haller D, Koletzko B, Koletzko S, Schwerd T. Partial enteral nutrition has no benefit on bone health but improves growth in paediatric patients with quiescent or mild Crohn's disease. Clin Nutr 2020;39:3786-96. [PMID: 32376096 DOI: 10.1016/j.clnu.2020.04.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Carlsen K, Frederiksen NW, Wewer V. Integration of eHealth Into Pediatric Inflammatory Bowel Disease Care is Safe: 3 Years of Follow-up of Daily Care. J Pediatr Gastroenterol Nutr 2021;72:723-7. [PMID: 33470751 DOI: 10.1097/MPG.0000000000003053] [Reference Citation Analysis]
49 De Carlo C, Bramuzzo M, Canaletti C, Udina C, Cozzi G, Pavanello PM, Rampado S, Martelossi S, Giudici F, Di Leo G, Barbi E. The Role of Distress and Pain Catastrophizing on the Health-related Quality of Life of Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;69:e99-e104. [PMID: 31335840 DOI: 10.1097/MPG.0000000000002447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
50 van den Brink G, Stapersma L, Bom AS, Rizopolous D, van der Woude CJ, Stuyt RJL, Hendriks DM, van der Burg JAT, Beukers R, Korpershoek TA, Theuns-Valks SDM, Utens EMWJ, Escher JC. Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial. Inflamm Bowel Dis 2019;25:1945-56. [PMID: 31050763 DOI: 10.1093/ibd/izz073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
51 Gervais L, Mclean LL, Wilson ML, Cameron C, Curtis L, Garrick V, Armstrong K, Tayler R, Henderson P, Hansen R, Chalmers I, Wilson DC, Russell RK. Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful. Journal of Pediatric Gastroenterology & Nutrition 2018;67:745-8. [DOI: 10.1097/mpg.0000000000002091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
52 van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P, Koletzko S, Kolho KL, Levine A, van Limbergen J, Martin de Carpi FJ, Navas-López VM, Oliva S, de Ridder L, Russell RK, Shouval D, Spinelli A, Turner D, Wilson D, Wine E, Ruemmele FM. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 2020:jjaa161. [PMID: 33026087 DOI: 10.1093/ecco-jcc/jjaa161] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 33.0] [Reference Citation Analysis]
53 Kammermeier J, Morris MA, Garrick V, Furman M, Rodrigues A, Russell RK. Management of Crohn’s disease. Arch Dis Child. 2016;101:475-480. [PMID: 26553907 DOI: 10.1136/archdischild-2014-307217] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
54 Schuman SL, Graef DM, Janicke DM, Gray WN, Hommel KA. An exploration of family problem-solving and affective involvement as moderators between disease severity and depressive symptoms in adolescents with inflammatory bowel disease. J Clin Psychol Med Settings 2013;20:488-96. [PMID: 23793840 DOI: 10.1007/s10880-013-9368-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
55 Choshen S, Turner D, Pratt LT, Precel R, Greer ML, Castro DA, Assa A, Martínez-León MI, Herman-Sucharska I, Coppenrath E, Konen O, Davila J, Bekhit E, Alsabban Z, Focht G, Gavish M, Griffiths A, Cytter-Kuint R. Development and Validation of a Pediatric MRI-Based Perianal Crohn Disease (PEMPAC) Index-A Report from the ImageKids Study. Inflamm Bowel Dis 2021:izab147. [PMID: 34151950 DOI: 10.1093/ibd/izab147] [Reference Citation Analysis]
56 Cozijnsen MA, Ben Shoham A, Kang B, Choe BH, Choe YH, Jongsma MME, Russell RK, Ruemmele FM, Escher JC, de Ridder L, Koletzko S, Martín-de-Carpi J, Hyams J, Walters T, Griffiths A, Turner D. Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:133-140.e1. [PMID: 30981008 DOI: 10.1016/j.cgh.2019.04.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
57 Cohen SA, Aloi M, Arumugam R, Baker R, Bax K, Kierkuś J, Koletzko S, Lionetti P, Persson T, Eklund S. Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children. Curr Med Res Opin 2017;33:1261-8. [PMID: 28420280 DOI: 10.1080/03007995.2017.1313213] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
58 Richmond L, Curtis L, Garrick V, Rogers P, Wilson M, Tayler R, Henderson P, Hansen R, Wilson DC, Russell RK. Biosimilar infliximab use in paediatric IBD. Arch Dis Child. 2018;103:89-91. [PMID: 28988215 DOI: 10.1136/archdischild-2017-313404] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
59 Shaoul R, Day AS. An Overview of Tools to Score Severity in Pediatric Inflammatory Bowel Disease. Front Pediatr 2021;9:615216. [PMID: 33912519 DOI: 10.3389/fped.2021.615216] [Reference Citation Analysis]
60 Arrigo S, Alvisi P, Banzato C, Bramuzzo M, Civitelli F, Corsello A, D'Arcangelo G, Dilillo A, Dipasquale V, Felici E, Fuoti M, Gatti S, Giusti Z, Knafelz D, Lionetti P, Mario F, Marseglia A, Martelossi S, Moretti C, Norsa L, Nuti F, Panceri R, Rampado S, Renzo S, Romano C, Romeo E, Strisciuglio C, Martinelli M. Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group. Dig Liver Dis. 2021;53:183-189. [PMID: 33132063 DOI: 10.1016/j.dld.2020.10.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
61 D’arcangelo G, Oliva S, Dilillo A, Viola F, Civitelli F, Isoldi S, Cucchiara S, Aloi M. Predictors of Long-term Clinical and Endoscopic Remission in Children With Crohn Disease Treated With Infliximab. Journal of Pediatric Gastroenterology & Nutrition 2019;68:841-6. [DOI: 10.1097/mpg.0000000000002262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
62 Rogler D, Fournier N, Pittet V, Bühr P, Heyland K, Friedt M, Koller R, Rueger V, Herzog D, Nydegger A, Schäppi M, Schibli S, Spalinger J, Rogler G, Braegger CP; Swiss IBD Cohort Study Group. Coping is excellent in Swiss Children with inflammatory bowel disease: results from the Swiss IBD cohort study. J Crohns Colitis 2014;8:409-20. [PMID: 24230970 DOI: 10.1016/j.crohns.2013.10.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
63 Molnár K, Vannay &, Szebeni B, Bánki NF, Sziksz E, Cseh &, Győrffy H, Lakatos PL, Papp M, Arató A, Veres G. Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease. World J Gastroenterol 2012; 18(25): 3254-3259 [PMID: 22783049 DOI: 10.3748/wjg.v18.i25.3254] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
64 Ankersen DV, Carlsen K, Marker D, Munkholm P, Burisch J. Using eHealth strategies in delivering dietary and other therapies in patients with irritable bowel syndrome and inflammatory bowel disease: eHealth strategies for IBS and IBD. Journal of Gastroenterology and Hepatology 2017;32:27-31. [DOI: 10.1111/jgh.13691] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
65 Dhaliwal J, Walters TD, Mack DR, Huynh HQ, Jacobson K, Otley AR, Debruyn J, El-Matary W, Deslandres C, Sherlock ME, Critch JN, Bax K, Seidman E, Jantchou P, Ricciuto A, Rashid M, Muise AM, Wine E, Carroll M, Lawrence S, Van Limbergen J, Benchimol EI, Church P, Griffiths AM. Phenotypic Variation in Paediatric Inflammatory Bowel Disease by Age: A Multicentre Prospective Inception Cohort Study of the Canadian Children IBD Network. J Crohns Colitis 2020;14:445-54. [PMID: 31136648 DOI: 10.1093/ecco-jcc/jjz106] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
66 Jones CMA, Connors J, Dunn KA, Bielawski JP, Comeau AM, Langille MGI, Van Limbergen J. Bacterial Taxa and Functions Are Predictive of Sustained Remission Following Exclusive Enteral Nutrition in Pediatric Crohn's Disease. Inflamm Bowel Dis 2020;26:1026-37. [PMID: 31961432 DOI: 10.1093/ibd/izaa001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
67 Fabian O, Hradsky O, Potuznikova K, Kalfusova A, Krskova L, Hornofova L, Zamecnik J, Bronsky J. Low predictive value of histopathological scoring system for complications development in children with Crohn’s disease. Pathology - Research and Practice 2017;213:353-8. [DOI: 10.1016/j.prp.2017.01.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
68 Cohen A, Ahmed N, Sant'Anna A. Ustekinumab for the treatment of refractory pediatric Crohn's disease: a single-center experience. Intest Res 2021;19:217-24. [PMID: 32312033 DOI: 10.5217/ir.2019.09164] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Mager DR, Carroll MW, Wine E, Siminoski K, Macdonald K, Kluthe CL, Medvedev P, Chen M, Wu J, Turner JM, Huynh HQ. Vitamin D status and risk for sarcopenia in youth with inflammatory bowel diseases. Eur J Clin Nutr 2018;72:623-6. [DOI: 10.1038/s41430-018-0105-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
70 Frivolt K, Schwerd T, Schatz SB, Freudenberg F, Prell C, Werkstetter KJ, Bufler P, Koletzko S. Hyperadiponectinemia During Infliximab Induction Therapy in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2018;66:915-9. [PMID: 29287006 DOI: 10.1097/MPG.0000000000001876] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
71 Heida A, Dijkstra A, Groen H, Muller Kobold A, Verkade H, van Rheenen P. Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials 2015;16:271. [PMID: 26073770 DOI: 10.1186/s13063-015-0787-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
72 Bramuzzo M, De Carlo C, Arrigo S, Pavanello PM, Canaletti C, Giudici F, Agrusti A, Martelossi S, Di Leo G, Barbi E. Parental Psychological Factors and Quality of Life of Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2020;70:211-7. [PMID: 31978019 DOI: 10.1097/MPG.0000000000002548] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
73 Weinstein-Nakar I, Focht G, Church P, Walters TD, Abitbol G, Anupindi S, Berteloot L, Hulst JM, Ruemmele F, Lemberg DA, Leach ST, Cytter R, Greer ML, Griffiths AM, Turner D; ImageKids study group. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease. Clin Gastroenterol Hepatol 2018; 16: 1089-1097. e4. [PMID: 29501599 DOI: 10.1016/j.cgh.2018.01.024] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 14.0] [Reference Citation Analysis]
74 Gourdonneau A, Bruneau L, Ruemmele FM, Norsa L, Takeda A, Le Gall C, Clouzeau H, Rebouissoux L, Dabadie A, Bridoux-Henno L, Rebeuh J, Thomassin N, Viala J, Willot S, Breton A, Coopman S, Spyckerelle C, Languepin J, Bertrand V, Mouterde O, Degas V, Bonneton M, Lemale J, Destombe S, Billiemaz K, Caron N, Borderon C, Dupont C, Triolo V, Jobert A, Lamireau T, Enaud R. Clinical Remission and Psychological Management are Major Issues for the Quality of Life in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2021;72:74-9. [PMID: 32740538 DOI: 10.1097/MPG.0000000000002865] [Reference Citation Analysis]
75 Weidlich S, Bulau AM, Schwerd T, Althans J, Kappler R, Koletzko S, Mayr D, Bufler P. Intestinal expression of the anti-inflammatory interleukin-1 homologue IL-37 in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014;59:e18-26. [PMID: 24732025 DOI: 10.1097/MPG.0000000000000387] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
76 Agrawal G, Hamblin H, Clancy A, Borody T. Anti-Mycobacterial Antibiotic Therapy Induces Remission in Active Paediatric Crohn's Disease. Microorganisms. 2020;8:1112. [PMID: 32722117 DOI: 10.3390/microorganisms8081112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
77 Frivolt K, Schwerd T, Werkstetter KJ, Schwarzer A, Schatz SB, Bufler P, Koletzko S. Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: predictors of efficacy and outcome. Aliment Pharmacol Ther. 2014;39:1398-1407. [PMID: 24779671 DOI: 10.1111/apt.12770] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
78 Dotson JL, Crandall WV, Zhang P, Forrest CB, Bailey LC, Colletti RB, Kappelman MD. Feasibility and validity of the pediatric ulcerative colitis activity index in routine clinical practice. J Pediatr Gastroenterol Nutr. 2015;60:200-204. [PMID: 25221935 DOI: 10.1097/mpg.0000000000000568] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
79 Rolandsdotter H, Jönsson-Videsäter K, L Fagerberg U, Finkel Y, Eberhardson M. Exclusive Enteral Nutrition: Clinical Effects and Changes in Mucosal Cytokine Profile in Pediatric New Inflammatory Bowel Disease. Nutrients 2019;11:E414. [PMID: 30781421 DOI: 10.3390/nu11020414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
80 Leach ST, Day AS, Messenger R, Walters TD, Navas-López VM, Sladek M, Brückner A, Yerushalmi B, Saeed S, Otley A, Mack D, Gavish M, Turner D, Griffiths AM, Lemberg DA; ImageKids study group. Fecal Markers of Inflammation and Disease Activity in Pediatric Crohn Disease: Results from the ImageKids Study. J Pediatr Gastroenterol Nutr 2020;70:580-5. [PMID: 31899733 DOI: 10.1097/MPG.0000000000002615] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
81 Lev-Tzion R, Griffiths AM, Leder O, Turner D. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;CD006320. [PMID: 24585498 DOI: 10.1002/14651858.cd006320.pub4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
82 Valério de Azevedo S, Maltez C, Lopes AI. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study. Scandinavian Journal of Gastroenterology 2017;52:29-33. [DOI: 10.1080/00365521.2016.1224381] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
83 Carman N, Tomalty D, Church PC, Mack DR, Benchimol EI, Otley AR, Jacobson K, Huynh HQ, DeBruyn JC, El-Matary W, Sherlock M, Van Limbergen J, Griffiths AM, Walters TD; Canadian Children Inflammatory Bowel Disease Network: A Joint Partnership of Canadian Institutes of Health Research and the Children with Intestinal and Liver Disorders Foundation. Clinical disease activity and endoscopic severity correlate poorly in children newly diagnosed with Crohn's disease. Gastrointest Endosc 2019;89:364-72. [PMID: 30273592 DOI: 10.1016/j.gie.2018.09.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
84 Takeuchi I, Arai K, Kyodo R, Sato T, Tokita K, Hirano Y, Shimizu H. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan. J Gastroenterol Hepatol 2021;36:125-30. [PMID: 32497325 DOI: 10.1111/jgh.15128] [Reference Citation Analysis]
85 Marques JG, Shokry E, Frivolt K, Werkstetter KJ, Brückner A, Schwerd T, Koletzko S, Koletzko B. Metabolomic Signatures in Pediatric Crohn's Disease Patients with Mild or Quiescent Disease Treated with Partial Enteral Nutrition: A Feasibility Study. SLAS Technol 2021;26:165-77. [PMID: 33207993 DOI: 10.1177/2472630320969147] [Reference Citation Analysis]
86 Church PC, Kuint RC, Ledder O, Navas-López VM, Sladek M, Brückner A, Baldassano RN, Weiss B, Yerushalmi B, Saeed SA, Hyams J, Otley A, Griffiths AM, Turner D, Greer MC; ImageKids Study group. Magnetic Resonance Enterography Cannot Replace Upper Endoscopy in Pediatric Crohn Disease: An Imagekids Sub-study. J Pediatr Gastroenterol Nutr 2018;67:53-8. [PMID: 29287012 DOI: 10.1097/MPG.0000000000001869] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
87 Frivolt K, Hetterich H, Schwerd T, Hajji M, Bufler P, Coppenrath E, Koletzko S. Increase of Intra-abdominal Adipose Tissue in Pediatric Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2017;65:633-8. [DOI: 10.1097/mpg.0000000000001593] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
88 Dolinger MT, Choi JJ, Phan BL, Rosenberg HK, Rowland J, Dubinsky MC. Use of Small Bowel Ultrasound to Predict Response to Infliximab Induction in Pediatric Crohn's Disease. J Clin Gastroenterol 2021;55:429-32. [PMID: 32453126 DOI: 10.1097/MCG.0000000000001367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
89 Alsabban Z, Church P, Moineddin R, Navarro OM, Greer M, Walters T, Chavhan GB. Accuracy and interobserver agreement of diffusion-weighted imaging in pediatric inflammatory bowel disease. Clinical Imaging 2017;41:14-22. [DOI: 10.1016/j.clinimag.2016.09.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
90 Copova I, Hradsky O, Zarubova K, Gonsorcikova L, Potuznikova K, Lerchova T, Nevoral J, Bronsky J. Fecal calprotectin is not a clinically useful marker for the prediction of the early nonresponse to exclusive enteral nutrition in pediatric patients with Crohn disease. Eur J Pediatr 2018;177:1685-93. [DOI: 10.1007/s00431-018-3228-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Singh N, Rabizadeh S, Jossen J, Pittman N, Check M, Hashemi G, Phan BL, Hyams JS, Dubinsky MC. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:2121-2126. [PMID: 27542130 DOI: 10.1097/mib.0000000000000865] [Cited by in Crossref: 60] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
92 Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, Dubinsky M, Heyman MB, de Ridder L, Hyams J, Martin de Carpi J, Conklin L, Faubion WA, Koletzko S, Bousvaros A, Ruemmele FM. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut 2020;69:32-41. [PMID: 30979718 DOI: 10.1136/gutjnl-2018-317987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
93 Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, Faubion W, Fell J, Gold BD, Griffiths A. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. Gastroenterology. 2017;152:1901-1914.e3. [PMID: 28193515 DOI: 10.1053/j.gastro.2017.02.004] [Cited by in Crossref: 114] [Cited by in F6Publishing: 95] [Article Influence: 28.5] [Reference Citation Analysis]
94 Merrick VM, Mortier K, Williams LJ, Muhammed R, Auth MK, Elawad M, Fell JM, Beattie RM, Loganathan S, Torrente F, Morris M, Charlton C, Croft NM, Rodrigues A, Furman M, Vadamalayan B, Jenkins H, Zamvar V, Mitton SG, Chong S, Cosgrove M, Akobeng A, Wilson DC, Russell RK. Real-life Anti-tumor Necrosis Factor Experience in More Than 500 Patients: High Co-immunosuppression Rates But Low Rates of Quantifying Treatment Response. Journal of Pediatric Gastroenterology & Nutrition 2018;66:274-80. [DOI: 10.1097/mpg.0000000000001679] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
95 Ezirike Ladipo J, He Z, Chikwava K, Robbins K, Beri J, Molle-Rios Z. Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort. J Pediatr Gastroenterol Nutr 2021;73:352-7. [PMID: 34117193 DOI: 10.1097/MPG.0000000000003201] [Reference Citation Analysis]
96 Valentino PL, Feldman BM, Walters TD, Griffiths AM, Ling SC, Pullenayegum EM, Kamath BM. Abnormal Liver Biochemistry Is Common in Pediatric Inflammatory Bowel Disease: Prevalence and Associations. Inflamm Bowel Dis 2015;21:2848-56. [PMID: 26273817 DOI: 10.1097/MIB.0000000000000558] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
97 Gallego-Gutiérrez S, Navas-López VM, Kolorz M, Bartosova L, Lukac K, Luque-Pérez S, Núñez-Caro L, García-Galán P, Fernández-Crehuet FG, Blasco-Alonso J, Serrano-Nieto MJ, Sierra-Salinas C. Successful Mercaptopurine Usage despite Azathioprine-Induced Pancreatitis in Paediatric Crohn's Disease. J Crohns Colitis 2015;9:676-9. [PMID: 25968582 DOI: 10.1093/ecco-jcc/jjv086] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
98 Reed-Knight B, Lobato D, Hagin S, McQuaid EL, Seifer R, Kopel SJ, Boergers J, Nassau JH, Suorsa K, Bancroft B, Shapiro J, Leleiko NS. Depressive symptoms in youth with inflammatory bowel disease compared with a community sample. Inflamm Bowel Dis. 2014;20:614-621. [PMID: 24518604 DOI: 10.1097/01.mib.0000442678.62674.b7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
99 Zaidi D, Churchill L, Huynh HQ, Carroll MW, Persad R, Wine E. Capillary Flow Rates in the Duodenum of Pediatric Ulcerative Colitis Patients Are Increased and Unrelated to Inflammation. J Pediatr Gastroenterol Nutr 2017;65:306-10. [PMID: 28045777 DOI: 10.1097/MPG.0000000000001495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
100 Ronel N, Tzion RL, Orlanski-Meyer E, Shteyer E, Guz-Mark A, Assa A, Strich D, Turner D, Ledder O. Clinical Criteria Can Identify Children With Osteopenia in Newly Diagnosed Crohn Disease. J Pediatr Gastroenterol Nutr 2021;72:270-5. [PMID: 32810035 DOI: 10.1097/MPG.0000000000002911] [Reference Citation Analysis]
101 van den Brink G, Stapersma L, El Marroun H, Henrichs J, Szigethy EM, Utens EM, Escher JC. Effectiveness of disease-specific cognitive-behavioural therapy on depression, anxiety, quality of life and the clinical course of disease in adolescents with inflammatory bowel disease: study protocol of a multicentre randomised controlled trial (HAPPY-IBD). BMJ Open Gastroenterol 2016;3:e000071. [PMID: 26966551 DOI: 10.1136/bmjgast-2015-000071] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
102 Hansen R, Sanderson IR, Muhammed R, Allen S, Tzivinikos C, Henderson P, Gervais L, Jeffery IB, Mullins DP, O'Herlihy EA, Weinberg JD, Kitson G, Russell RK, Wilson DC. A Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability of (Thetanix) Bacteroides thetaiotaomicron in Adolescent Crohn's Disease. Clin Transl Gastroenterol 2020;12:e00287. [PMID: 33464732 DOI: 10.14309/ctg.0000000000000287] [Reference Citation Analysis]
103 Colman RJ, Tsai YT, Jackson K, Boyle BM, Noe JD, Hyams JS, D'Haens GRAM, van Limbergen J, Rosen MJ, Denson LA, Minar P. Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. Inflamm Bowel Dis 2021;27:1045-51. [PMID: 32944769 DOI: 10.1093/ibd/izaa241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
104 Atia O, Ledder O, Ben-moshe T, Lev-tzion R, Rachmen Y, Meyer EO, Beeri R, Renbaum P, Shamasneh I, Shteyer E, Turner D. Role of Thiopurines in Pediatric Inflammatory Bowel Diseases: A Real-Life Prospective Cohort Study. Journal of Pediatric Gastroenterology & Nutrition 2020;70:825-32. [DOI: 10.1097/mpg.0000000000002566] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
105 Kaplan HC, Opipari-Arrigan L, Schmid CH, Schuler CL, Saeed S, Braly KL, Burgis JC, Nguyen K, Pilley S, Stone J, Woodward G, Suskind DL. Evaluating the Comparative Effectiveness of Two Diets in Pediatric Inflammatory Bowel Disease: A Study Protocol for a Series of N-of-1 Trials. Healthcare (Basel) 2019;7:E129. [PMID: 31683925 DOI: 10.3390/healthcare7040129] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
106 Lee MN, Kang B, Choi SY, Kim MJ, Woo SY, Kim JW, Choe YH, Lee SY. Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine. Inflamm Bowel Dis 2015;21:1054-62. [PMID: 25851563 DOI: 10.1097/MIB.0000000000000347] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 7.2] [Reference Citation Analysis]
107 Svolos V, Hansen R, Nichols B, Quince C, Ijaz UZ, Papadopoulou RT, Edwards CA, Watson D, Alghamdi A, Brejnrod A, Ansalone C, Duncan H, Gervais L, Tayler R, Salmond J, Bolognini D, Klopfleisch R, Gaya DR, Milling S, Russell RK, Gerasimidis K. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition. Gastroenterology 2019;156:1354-1367.e6. [PMID: 30550821 DOI: 10.1053/j.gastro.2018.12.002] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 31.0] [Reference Citation Analysis]
108 Morita M, Takeuchi I, Kato M, Migita O, Jimbo K, Shimizu H, Yoshimura S, Tomizawa D, Shimizu T, Hata K, Ishiguro A, Arai K. Intestinal outcome of bone marrow transplantation for monogenic inflammatory bowel disease. Pediatr Int 2021. [PMID: 33884705 DOI: 10.1111/ped.14750] [Reference Citation Analysis]
109 Turner D, Levine A, Walters TD, Focht G, Otley A, López VN, Koletzko S, Baldassano R, Mack D, Hyams J. Which PCDAI Version Best Reflects Intestinal Inflammation in Pediatric Crohn’s Disease? J Pediatr Gastroenterol Nutr. 2016; Epub ahead of print. [PMID: 27050050 DOI: 10.1097/mpg.0000000000001227] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 12.7] [Reference Citation Analysis]
110 Gatti S, Brennan M, Heuschkel R, Zilbauer M. Assessing quality of care in paediatric inflammatory bowel disease: Focusing on self-reported outcomes. Digestive and Liver Disease 2015;47:347-8. [DOI: 10.1016/j.dld.2014.11.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
111 Cozijnsen MA, van Pieterson M, Samsom JN, Escher JC, de Ridder L. Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial. BMJ Open Gastroenterol 2016;3:e000123. [PMID: 28090335 DOI: 10.1136/bmjgast-2016-000123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
112 Grant A, Lerer T, Griffiths AM, Hyams J, Otley A. Assessing disease activity using the pediatric Crohn’s disease activity index: Can we use subjective or objective parameters alone? World J Gastroenterol 2021; 27(30): 5100-5111 [PMID: 34497438 DOI: 10.3748/wjg.v27.i30.5100] [Reference Citation Analysis]